CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells. 2021

Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
Department of Neurosurgery, Nara Medical University, Kashihara, Nara 634-8521, Japan.

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults. Natural Killer (NK) cells are potent cytotoxic effector cells against tumor cells inducing GBM cells; therefore, NK cell based- immunotherapy might be a promising target in GBM. T cell immunoglobulin mucin family member 3 (TIM3), a receptor expressed on NK cells, has been suggested as a marker of dysfunctional NK cells. We established TIM3 knockout in NK cells, using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9). Electroporating of TIM3 exon 2- or exon 5-targeting guide RNA- Cas9 protein complexes (RNPs) inhibited TIM3 expression on NK cells with varying efficacy. T7 endonuclease I mutation detection assays showed that both RNPs disrupted the intended genome sites. The expression of other checkpoint receptors, i.e., programmed cell death 1 (PD1), Lymphocyte-activation gene 3 (LAG3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), and TACTILE (CD96) were unchanged on the TIM3 knockout NK cells. Real time cell growth assays revealed that TIM3 knockout enhanced NK cell-mediated growth inhibition of GBM cells. These results demonstrated that TIM3 knockout enhanced human NK cell mediated cytotoxicity on GBM cells. Future, CRISPR-Cas9 mediated TIM3 knockout in NK cells may prove to be a promising immunotherapeutic alternative in patient with GBM.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072597 Hepatitis A Virus Cellular Receptor 2 An Ig domain-containing membrane receptor that is expressed by TH1 CELLS. It regulates the activation of MACROPHAGES and inhibits TH1-mediated auto- and alloimmune responses to promote IMMUNE TOLERANCE. CD366 Antigen,HAVCR2 Protein,T-Cell Immunoglobulin Mucin Receptor 3,T-Cell Immunoglobulin and Mucin Domain-Containing Protein 3,TIMD3 Protein,Antigen, CD366,T Cell Immunoglobulin Mucin Receptor 3,T Cell Immunoglobulin and Mucin Domain Containing Protein 3
D000094704 RNA, Guide, CRISPR-Cas Systems A component of CRISPR-Cas SYSTEMS. Cas endodeoxyribonucleases assemble with a guide RNA complex, a hybrid of CRISPR RNA (crRNA) and transactivating crRNA (tracrRNA) molecules, to form an active complex that cleaves DNA. crRNA and tracrRNA can be synthetically fused into a single RNA molecule, namely single guide RNA. Synthetic sgRNA is used with CRISPR-Cas SYSTEMS for targeted GENE EDITING. CRISPR Guide RNA,CRISPR-Cas Systems sgRNA (Single Guide RNA),Guide RNA (CRISPR-Cas Systems),Guide RNA, CRISPR-Cas Systems,RNA, CRISPR Guide,RNA, Guide (CRISPR-Cas Systems),RNA, Single Guide,RNA, Single-Guide,Single Guide RNA,Single-Guide RNA,Transactivating crRNA,crRNA,crRNA, Transactivating,sgRNA (CRISPR-Cas Systems),sgRNA (Single-Guide RNA),tracrRNA,Guide RNA, CRISPR,Guide RNA, CRISPR Cas Systems,Guide RNA, Single
D015894 Genome, Human The complete genetic complement contained in the DNA of a set of CHROMOSOMES in a HUMAN. The length of the human genome is about 3 billion base pairs. Human Genome,Genomes, Human,Human Genomes
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
December 2020, Adipocyte,
Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
January 2022, Methods in molecular biology (Clifton, N.J.),
Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
January 2020, Methods in molecular biology (Clifton, N.J.),
Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
June 2023, Molecular therapy. Methods & clinical development,
Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
January 2021, BMC biotechnology,
Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
January 2024, Nucleic acids research,
Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
January 2020, Frontiers in immunology,
Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
January 2020, EXCLI journal,
Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
January 2014, Science (New York, N.Y.),
Takayuki Morimoto, and Tsutomu Nakazawa, and Ryosuke Matsuda, and Fumihiko Nishimura, and Mitsutoshi Nakamura, and Shuichi Yamada, and Ichiro Nakagawa, and Young-Soo Park, and Takahiro Tsujimura, and Hiroyuki Nakase
August 2018, Cancer research,
Copied contents to your clipboard!